Nootropic
Noopept
SaveA synthetic dipeptide (N-phenylacetyl-L-prolylglycine ethyl ester) developed in Russia, proposed to modulate AMPA and NMDA receptors and increase BDNF/NGF expression.
Quick verdict
Approved in Russia for cognitive disorders. Western evidence is limited to preclinical and a few small clinical studies. Popular among nootropic users for perceived clarity.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Russian clinical trials report cognitive benefits in patients with organic brain disorders and post-concussion syndrome. Animal studies show anxiolytic and pro-cognitive effects. Western peer-reviewed literature is sparse.
Benefits
- Increases BDNF and NGF in rodent hippocampus
- Reported cognitive improvement in post-concussion patients in Russian trials
- Active at very low doses (10–30 mg)
Dosage notes
10–30 mg/day sublingually or orally, typically in 2–3 divided doses. Cycle use is often recommended.
Side effects
- Irritability
- Headache (possibly from choline depletion)
- Insomnia
Who should be cautious
Not approved outside Russia. May interact with other psychoactive substances. Avoid in pregnancy.
What this page cannot tell you
Most clinical evidence is from Russian studies not replicated independently in Western trials.
Leaderboard scores
- Memory50
- Focus50
- Anxiety35
- Mood35
Write a review
Sign in to write a review.